The History of AIDS: Timeline of the History of HIV/AIDS: 1991 - 1992
A Chronology of Significant Events
(as of 4/20/05)
On May 30, FDA authorized pre-approval distribution of dideoxycytidine (ddC) under
a treatment IND protocol for the treatment of patients with AIDS or advanced AIDS
Related Complex who cannot be maintained on zidovudine (AZT).
On September 27, FDA approved Foscavir (foscarnet) for use in the treatment of cytomegalovirus
retinal infections in persons with AIDS.
On October 9, FDA approved Videx (didanosine, ddI) for the treatment of adult and
pediatric patients (over 6 months of age) with advanced HIV infection. This approval
involved the historic joint review between officials at FDA and our regulatory counterparts
The first combination test to detect HIV-1 and HIV-2 antibodies was licensed.
On November 8, FDA authorized pre-approval distribution of atovaquone under a treatment
IND protocol to patients who have Pneumocystis carinii pneumonia and cannot tolerate
trimethoprim sulfamethoxazole, a standard treatment for this condition.
On March 6, FDA authorized pre-approval distribution of rifabutin under a treatment
IND protocol for preventing or delaying the onset of Mycobacterium avium complex,
a severe infection that often afflicts AIDS patients.
On May 27, FDA licensed SUDS HIV-1, a ten minute diagnostic test kit which can be
used by health professionals to detect the presence of HIV-1.
On June 19, FDA approved zalcitabine, commonly known as ddC, for use in combination
with zidovudine (AZT) as a treatment option for adult patients with advanced HIV
infection who show signs of clinical or immunological deterioration. Zalcitabine,
manufactured and distributed by Hoffmann-La Roche under the trade name Hivid, was
the first drug approved under the principles and procedures of FDA's proposed accelerated
drug approval policy.
On September 11, FDA approved Sporanox (itraconazole) for the treatment of blastomycosis
and histoplasmosis in immunocompromised and non-immunocompromised patients.
On September 25, FDA approved new labeling for Videx (didanosine, ddI). The data
demonstrated that the lower dose of ddI is equally efficacious and associated with
lower rates of toxicity, especially pancreatitis.
On October 5, d4T (stavudine) was the first drug made available for expanded investigational
use under the parallel track policy.
On October 8, FDA approved new labeling for nonprescription drugs for vaginal candidiasis.
The revised labeling advised women that frequent or persistent cases of vaginal fungal
infections may sometimes be an early warning of HIV infection.
On November 25, FDA approved Mepron (atovaquone) for the treatment of mild to moderate
PCP in patients who are intolerant of trimethoprim-sulfamethoxazole, the standard
On December 22, FDA approved Marinol (dronabinol) for a new indication for the treatment
of anorexia and weight loss associated with AIDS.
On December 23, FDA approved Mycobutin (rifabutin) for prophylaxis against Mycobacterium
avium complex, a severe infection that often afflicts AIDS patients.
1981 - 1987 ...Last ||| Next... 1993 - 1994
The History of AIDS © 2005
Legal Disclaimer: "The History of AIDS" is not affiliated
in any way with the organizations, or third party links found at this website, with
the exception of links to Amazon.com. The information at this website should not
be taken as medical advice, treatment, or diagnosis, express or implied. Even though
a reasonable effort has been made to present correct information, no warranty is
made that the data at this website is true or accurate. Consult your health care
professional before beginning ANY treatment or regimen.
Member of Fohn.net